CEO Doug Biehn sits down with Nasdaq’s Leigh Hixon to share Octave’s vision of transforming neurodegenerative disease care through precision medicine. Watch Now

Get in Touch

Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Improving Patient Outcomes through a Comprehensive Care Management Platform Measuring Outcomes and Value: an Integrated, Novel solution for Generating insights in MS (MOVING MS)

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020

BrainGraph: A Novel Visualization of MRI Data as a 3D Graph to Reveal Temporal Features of Disease Progression In Patients with Multiple Sclerosis

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020

High throughput lesion evaluation and quality control for incorporating quantitative imaging metrics into clinical practice

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020

Multivariate protein biomarker models more accurately predict multiple sclerosis MRI disease activity compared to serum levels of neurofilament light chain alone

  • Research Presented at ECTRIMS 2019 Stockholm, Sweden — September 11-13, 2019
Download PDF

Classification of high versus low annualized relapse rate status in subjects with relapsing-remitting multiple sclerosis using multivariate serum protein biomarker models

  • Research Presented at ECTRIMS 2019 Stockholm, Sweden — September 11-13, 2019

Clinical disease activity status (exacerbation versus quiescence) in subjects with relapsing-remitting multiple sclerosis is accurately classified using multivariate serum protein biomarker models

  • Research Presented at ECTRIMS 2019 Stockholm, Sweden — September 11-13, 2019

Clinical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in Multiple Sclerosis

  • Research Presented at the Annual ACTRIMS Meeting Virtual Conference — February 25-27, 2021
Download PDF

Improved detection of clinically relevant MRI findings in Multiple Sclerosis radiology reports using FDA-approved quantitative software

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020
Download PDF

From proteome to interactome: a mechanistic approach to MS biomarker discovery

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020
Download PDF

Cross-sectional and longitudinal estimation of radiographic and clinical endpoints to quantify MS disease trajectory with blood serum protein levels.

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020
Download PDF
1 … 7 8 9

Improving Patient Outcomes through a Comprehensive Care Management Platform Measuring Outcomes and Value: an Integrated, Novel solution for Generating insights in MS (MOVING MS)

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020

BrainGraph: A Novel Visualization of MRI Data as a 3D Graph to Reveal Temporal Features of Disease Progression In Patients with Multiple Sclerosis

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020

High throughput lesion evaluation and quality control for incorporating quantitative imaging metrics into clinical practice

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020

Multivariate protein biomarker models more accurately predict multiple sclerosis MRI disease activity compared to serum levels of neurofilament light chain alone

  • Research Presented at ECTRIMS 2019 Stockholm, Sweden — September 11-13, 2019
Download PDF

Classification of high versus low annualized relapse rate status in subjects with relapsing-remitting multiple sclerosis using multivariate serum protein biomarker models

  • Research Presented at ECTRIMS 2019 Stockholm, Sweden — September 11-13, 2019

Clinical disease activity status (exacerbation versus quiescence) in subjects with relapsing-remitting multiple sclerosis is accurately classified using multivariate serum protein biomarker models

  • Research Presented at ECTRIMS 2019 Stockholm, Sweden — September 11-13, 2019

Clinical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in Multiple Sclerosis

  • Research Presented at the Annual ACTRIMS Meeting Virtual Conference — February 25-27, 2021
Download PDF

Improved detection of clinically relevant MRI findings in Multiple Sclerosis radiology reports using FDA-approved quantitative software

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020
Download PDF

From proteome to interactome: a mechanistic approach to MS biomarker discovery

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020
Download PDF

Cross-sectional and longitudinal estimation of radiographic and clinical endpoints to quantify MS disease trajectory with blood serum protein levels.

  • Research Presented at the Joint ACTRIMS-ECTRIMS Meeting MS Virtual 2020 — September 11-13, 2020
Download PDF
Load More

© 2024 Octave Bioscience, Inc | 1440 O’Brien Drive, Suite B, Menlo Park, CA 94025 

Connect with us